WESTLAKE VILLAGE, Calif., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a late-stage biopharmaceutical company focused on developing and commercializing treatments ...

FERNDALE, Michigan and NESS ZIONA, Israel, June 3 /PRNewswire/ -- Ferndale Laboratories Inc. and Foamix Ltd. announced today that the two companies executed a license agreement for Ferndale to develop ...

Please provide your email address to receive an email when new articles are posted on . Arcutis Biotherapeutics will begin a phase 3 trial of roflumilast foam for the treatment of seborrheic ...

Nuvo Research Inc. (TSX:NRI), a specialty pharmaceutical company with a diverse portfolio of topical and immunology products, today announced that the United States Patent Office has granted U.S.

NDA supported by positive efficacy and safety data from the Phase 2 and pivotal Phase 3 trials of roflumilast foam If approved, roflumilast foam would be the first topical drug for seborrheic ...

The US Food and Drug Administration (FDA) has agreed to review a new drug application (NDA) for roflumilast foam 0.3% for treating seborrheic dermatitis in patients ages 9 years and older. If approved ...

The Food and Drug Administration (FDA) announced that it has accepted the supplemental New Drug Application (sNDA) for roflumilast foam 0.3% in adults and adolescents with scalp and body psoriasis ...

Please provide your email address to receive an email when new articles are posted on . Cal/BDP is a combination formula, comprised of calcipotriol and betamethasone dipropionate, that treats ...

Collaborative partnerships can foster success in formulation development projects. The formulation development outsourcing market is expected to grow at a compound annual rate of 7.2% between 2021 and ...

Foam is for more than just bubble baths — an Israeli medical development firm has found dozens of beneficial uses. One of the most promising is an acne treatment that researchers say is more effective ...